Incidence and Risk factors of Intraocular Inflammation after Brolucizumab Treatment in Japan: A Multicenter AMD Study.

Satoru InodaHidenori TakahashiMaiko Maruyama-InoueShoko IkedaTetsuju SekiryuKanako ItagakiHidetaka MatsumotoRyo MukaiYoshimi NagaiMasayuki OhnakaSentaro KusuharaAkiko MikiAnnabelle A OkadaMakiko NakayamaKoji M NishiguchiJun TakeuchiRyusaburo MoriKoji TanakaShigeru HondaTakeya KohnoHideki KoizumiYasunori MiyaraYuji InoueHiroki TakanaTomohiro IidaIchiro MarukoAtsushi HayashiTomoko Ueda-ConsolvoYasuo Yanagi

Published in: Retina (Philadelphia, Pa.) (2023)

The 1-year cumulative incidence of IOI in Japanese nAMD patients treated with brolucizumab was 12.2%. Prior history of IOI (including RV) and/or RO and female sex were significant risk factors.

Keyphrases

risk factors
mycobacterium tuberculosis
oxidative stress
clinical trial
smoking cessation
cataract surgery